MedTrace Logo

Acetazolamide Trial in Normal Pressure Hydrocephalus

NCT04975269 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-05-06

No results posted yet for this study

Summary

A pharmacological treatment to patients with normal pressure hydrocephalus (NPH) is missing. The aim is to investigate if acetazolamide given to patients with NPH improves gait function and study the pathophysiological mechanisms leading to reduced symptoms.

Patients will be randomized to acetazolamide or placebo and duration of treatment will be from diagnosis to the day of shunt surgery. Target dose is 500 mg/day. Study design is a double-blind randomized controlled trial and the plan is to include 42-50 patients. The study is investigator-initiated without financial sponsorship from the industry.

Conditions

  • Idiopathic Normal Pressure Hydrocephalus (INPH)

Interventions

DRUG

Acetazolamide

Target dose: 500 mg / day

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Uppsala University

    collaborator OTHER

  • Swedish Society for Medical Research

    collaborator OTHER

  • Uppsala University Hospital

    lead OTHER

Principal Investigators

  • Johan Virhammar, MD, PhD · Department of Neuroscience, Uppsala University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
82 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-17
Primary Completion
2024-11-18
Completion
2026-04-21

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04975269 on ClinicalTrials.gov